SCHEDULE: Commander Aggregator Cuts Compass Therapeutics Stake Below 5%

Commander Aggregator, LP and related entities report their beneficial ownership in Compass Therapeutics, Inc. has fallen to 4.5% due to an increase in the issuer's outstanding shares.

Summary

• Commander Aggregator, LP, along with Enavate Sciences, LP, Enavate Sciences GP, LLC, and Enavate Sciences Holdings, LLC, collectively hold 7,788,150 shares of Compass Therapeutics, Inc. common stock.
• This represents 4.5% of the total outstanding shares of Compass Therapeutics, Inc.
• The percentage ownership decreased from above 5% to 4.5% because Compass Therapeutics, Inc. increased its total outstanding shares to 171,572,498 shares, effective August 14, 2025.
• This increase in outstanding shares was reported by Compass Therapeutics, Inc. in a Prospectus filed with the SEC on August 13, 2025.
• The reporting entities did not engage in any transactions involving Compass Therapeutics, Inc. common stock in the past 60 days.
• As a result of their beneficial ownership falling below the 5% threshold, the reporting entities are no longer subject to Section 13 reporting requirements.

Sentiment

Score: 6

Explanation: The filing itself is a routine regulatory update. For the reporting entity, it means less reporting burden. For the issuer, the underlying event (increase in outstanding shares) likely signifies a successful capital raise, which is generally positive for a biotech company needing funds, despite the dilution for existing shareholders.

Positives

• The reporting entities maintained their share count, indicating continued belief in the company despite the dilution of their percentage ownership.
• The issuer successfully increased its outstanding shares, likely through a capital raise, which could provide funding for operations and development.

Negatives

• The reporting entities' percentage ownership in Compass Therapeutics, Inc. has been diluted from above 5% to 4.5%.

Risks

• Dilution of existing shareholders' percentage ownership due to the increase in outstanding shares.

Future Outlook

The reporting entities are no longer subject to Section 13 reporting requirements as their beneficial ownership has fallen below 5%.

Industry Context

This filing reflects a change in a significant investor's reporting status due to a capital event (likely a share issuance) by a biotechnology company. Such capital raises are common in the biotech industry to fund research, development, and clinical trials.

Comparison to Industry Standards

• This filing is a standard regulatory disclosure of a change in beneficial ownership.
• The percentage of ownership falling below 5% due to an increase in outstanding shares is a common occurrence when companies raise capital through equity offerings. Specific comparable companies or projects are not relevant here as this is a reporting compliance update for an investor.

Stakeholder Impact

• Shareholders: Existing shareholders of Compass Therapeutics, Inc. experienced dilution of their percentage ownership due to the increase in outstanding shares.
• Reporting Entities: Commander Aggregator, LP and related entities are no longer required to file Section 13 reports for their holdings in Compass Therapeutics, Inc.

Next Steps

• The reporting entities are no longer subject to Section 13 reporting requirements for Compass Therapeutics, Inc. shares.

Key Dates

Recommendation

This filing primarily details a change in reporting status for a significant investor due to an increase in the issuer's outstanding shares, likely from a capital raise. It does not provide new information about the company's operations, financial performance, or strategic direction that would warrant a change in investment thesis. The dilution is a known consequence of capital raises in the biotech sector. Therefore, a 'hold' recommendation is appropriate, pending further operational or financial updates from Compass Therapeutics, Inc.

Keywords

Compass Therapeutics, CTIC, Commander Aggregator, Enavate Sciences, Schedule 13D, beneficial ownership, stock ownership, SEC filing, biotechnology, capital raise, dilution